Related references
Note: Only part of the references are listed.An atlas of substrate specificities for the human serine/threonine kinome
Jared L. Johnson et al.
NATURE (2023)
Properties of FDA-approved small molecule protein kinase inhibitors: A 2023 update
Robert Roskoski Jr
PHARMACOLOGICAL RESEARCH (2023)
DYRK1A Inhibitors and Perspectives for the Treatment of Alzheimer's Disease
Marcia Maria de Souza et al.
CURRENT MEDICINAL CHEMISTRY (2023)
An overview of cdc2-like kinase 1 (Clk1) inhibitors and their therapeutic indications
Ahmed K. ElHady et al.
MEDICINAL RESEARCH REVIEWS (2023)
Suppression of DYRK1A/B Drives Endoplasmic Reticulum Stress-mediated Autophagic Cell Death Through Metabolic Reprogramming in Colorectal Cancer Cells
Jieon Hwang et al.
ANTICANCER RESEARCH (2022)
ARN25068, a versatile starting point towards triple GSK-3β/FYN/ DYRK1A inhibitors to tackle tau-related neurological disorders
Stefania Demuro et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2022)
Structure-activity relationship for the folding intermediate-selective inhibition of DYRK1A
Yuka Miyazaki et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2022)
DYRK1A inhibitors for disease therapy: Current status and perspectives
Tong Liu et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2022)
Structure-Activity Relationship in the Leucettine Family of Kinase Inhibitors
Tania Tahtouh et al.
JOURNAL OF MEDICINAL CHEMISTRY (2022)
CRISPR-Cas9 Screen Identifies DYRK1A as a Target for Radiotherapy Sensitization in Pancreatic Cancer
Bin Lan et al.
CANCERS (2022)
Cerebral Phospho-Tau Acts Synergistically with Soluble Aβ42 Leading to Mild Cognitive Impairment in AAV-AD Rats
B. Souchet et al.
JPAD-JOURNAL OF PREVENTION OF ALZHEIMERS DISEASE (2022)
Design, synthesis, and biological evaluation of polyphenol derivatives as DYRK1A inhibitors. The discovery of a potentially promising treatment for Multiple Sclerosis
Gian Luca Arald et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2022)
Harmine-based dual inhibitors targeting histone deacetylase (HDAC) and DNA as a promising strategy for cancer therapy
Dehua Lu et al.
BIOORGANIC CHEMISTRY (2022)
A review of FLT3 inhibitors in acute myeloid leukemia
Jennifer C. Zhao et al.
BLOOD REVIEWS (2022)
Desmethylbellidifolin Attenuates Dextran Sulfate Sodium-Induced Colitis: Impact on Intestinal Barrier, Intestinal Inflammation and Gut Microbiota
Jiaqi Wu et al.
PLANTA MEDICA (2022)
Selective Macrocyclic Inhibitors of DYRK1A/B
Chelsea E. Powell et al.
ACS MEDICINAL CHEMISTRY LETTERS (2022)
Catechins as a Potential Dietary Supplementation in Prevention of Comorbidities Linked with Down Syndrome
Christophe Noll et al.
NUTRIENTS (2022)
Selective inhibition reveals the regulatory function of DYRK2 in protein synthesis and calcium entry
Tiantian Wei et al.
ELIFE (2022)
Epigallocatechin-3-Gallate (EGCG): New Therapeutic Perspectives for Neuroprotection, Aging, and Neuroinflammation for the Modern Age
Ashley Payne et al.
BIOMOLECULES (2022)
Safety and preliminary efficacy on cognitive performance and adaptive functionality of epigallocatechin gallate (EGCG) in children with Down syndrome. A randomized phase Ib clinical trial (PERSEUS study)
Cecile Cieuta-Walti et al.
GENETICS IN MEDICINE (2022)
Structural features of the protein kinase domain and targeted binding by small-molecule inhibitors
Chris Arter et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2022)
Expression and purification of DYRK1A kinase domain in complex with its folding intermediate-selective inhibitor FINDY
Ninako Kimura et al.
PROTEIN EXPRESSION AND PURIFICATION (2022)
DYRK1a Inhibitor Mediated Rescue of Drosophila Models of Alzheimer's Disease-Down Syndrome Phenotypes
Bangfu Zhu et al.
FRONTIERS IN PHARMACOLOGY (2022)
The Omnipresence of DYRK1A in Human Diseases
Estelle Deboever et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)
Dual-specificity Tyrosine Phosphorylation-regulated Kinase Inhibitor ID-8 Promotes Human Somatic Cell Reprogramming by Activating PDK4 Expression
Jinhong Xu et al.
STEM CELL REVIEWS AND REPORTS (2022)
DYRK1a Inhibitor Mediated Rescue of Drosophila Models of Alzheimer's Disease-Down Syndrome Phenotypes
Bangfu Zhu et al.
FRONTIERS IN PHARMACOLOGY (2022)
DYRK1A: a down syndrome-related dual protein kinase with a versatile role in tumorigenesis
Amina Jamal Laham et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2021)
Abemaciclib, a third CDK 4/6 inhibitor for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced or metastatic breast cancer
Georges El Hachem et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2021)
Preclinical discovery and development of abemaciclib used to treat breast cancer
Matthew D. Wright et al.
EXPERT OPINION ON DRUG DISCOVERY (2021)
Novel pharmacotherapy: NNI-362, an allosteric p70S6 kinase stimulator, reverses cognitive and neural regenerative deficits in models of aging and disease
Nathalie Sumien et al.
STEM CELL RESEARCH & THERAPY (2021)
Targeting DYRK1A/B kinases to modulate p21-cyclin D1-p27 signalling and induce anti-tumour activity in a model of human glioblastoma
Andrew J. Massey et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2021)
Discovery of DB18, a potent inhibitor of CLK kinases with a high selectivity against DYRK1A kinase
Dabbugoddu Brahmaiah et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2021)
Aristolactam BIII, a naturally derived DYRK1A inhibitor, rescues Down syndrome-related phenotypes
Miri Choi et al.
PHYTOMEDICINE (2021)
A small molecule produced by Lactobacillus species blocks Candida albicans filamentation by inhibiting a DYRK1-family kinase
Jessie MacAlpine et al.
NATURE COMMUNICATIONS (2021)
Abemaciclib is a potent inhibitor of DYRK1A and HIP kinases involved in transcriptional regulation
Ines H. Kaltheuner et al.
NATURE COMMUNICATIONS (2021)
Dyrk1a from Gene Function in Development and Physiology to Dosage Correction across Life Span in Down Syndrome
Helin Atas-Ozcan et al.
GENES (2021)
Structure-Guided Discovery of Potent and Selective DYRK1A Inhibitors
Csaba Weber et al.
JOURNAL OF MEDICINAL CHEMISTRY (2021)
Novel DYRK1A Inhibitor Rescues Learning and Memory Deficits in a Mouse Model of Down Syndrome
Wenche Stensen et al.
PHARMACEUTICALS (2021)
Kinase drug discovery 20 years after imatinib: progress and future directions
Philip Cohen et al.
NATURE REVIEWS DRUG DISCOVERY (2021)
Synthesis of novel 1H-Pyrazolo[3,4-b]pyridine derivatives as DYRK 1A/1B inhibitors
Areum Park et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2021)
GSK-3β, FYN, and DYRK1A: Master Regulators in Neurodegenerative Pathways
Stefania Demuro et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
Dual-Specificity, Tyrosine Phosphorylation-Regulated Kinases (DYRKs) and cdc2-Like Kinases (CLKs) in Human Disease, an Overview
Mattias F. Lindberg et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
Fragment-Derived Selective Inhibitors of Dual-Specificity Kinases DYRK1A and DYRK1B
David Lee Walmsley et al.
JOURNAL OF MEDICINAL CHEMISTRY (2021)
Discovery and Characterization of Selective and Ligand-Efficient DYRK Inhibitors
Scott H. Henderson et al.
JOURNAL OF MEDICINAL CHEMISTRY (2021)
Development of Cdc2-like Kinase 2 Inhibitors: Achievements and Future Directions
Zhen Qin et al.
JOURNAL OF MEDICINAL CHEMISTRY (2021)
Trends in kinase drug discovery: targets, indications and inhibitor design
Misty M. Attwood et al.
NATURE REVIEWS DRUG DISCOVERY (2021)
Simultaneous CK2/TNIK/DYRK1 inhibition by 108600 suppresses triple negative breast cancer stem cells and chemotherapy-resistant disease
Katsutoshi Sato et al.
NATURE COMMUNICATIONS (2021)
A natural DYRK1A inhibitor as a potential stimulator for β-cell proliferation in diabetes
Mengzhu Zheng et al.
CLINICAL AND TRANSLATIONAL MEDICINE (2021)
A novel class of inhibitors that target SRSF10 and promote p53-mediated cytotoxicity on human colorectal cancer cells
Muhammad Sohail et al.
NAR CANCER (2021)
SM04755, a small-molecule inhibitor of the Wnt pathway, as a potential topical treatment for tendinopathy
Vishal Deshmukh et al.
JOURNAL OF ORTHOPAEDIC RESEARCH (2021)
The CLK inhibitor SM08502 induces anti-tumor activity and reduces Wnt pathway gene expression in gastrointestinal cancer models
Betty Y. Tam et al.
CANCER LETTERS (2020)
Synthesis and Biological Validation of a Harmine-Based, Central Nervous System (CNS)-Avoidant, Selective, Human β-Cell Regenerative Dual-Specificity Tyrosine Phosphorylation-Regulated Kinase A (DYRK1A) Inhibitor
Kunal Kumar et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Selective DYRK1A Inhibitor for the Treatment of Type 1 Diabetes: Discovery of 6-Azaindole Derivative GNF2133
Yahu A. Liu et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
The kinase polypharmacology landscape of clinical PARP inhibitors
Albert A. Antolin et al.
SCIENTIFIC REPORTS (2020)
Structure-Activity Relationships and Biological Evaluation of 7-Substituted Harmine Analogs for Human β-Cell Proliferation
Kunal Kumar et al.
MOLECULES (2020)
Targeting the trypanosome kinetochore with CLK1 protein kinase inhibitors
Manuel Saldivia et al.
NATURE MICROBIOLOGY (2020)
Development of Potent PfCLK3 Inhibitors Based on TCMDC-135051 as a New Class of Antimalarials
Amit Mahindra et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Cdc-Like Kinases (CLKs): Biology, Chemical Probes, and Therapeutic Potential
Paula Martin Moyano et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Synergistic apoptotic effects in cancer cells by the combination of CLK and Bcl-2 family inhibitors
Aiko Murai et al.
PLOS ONE (2020)
Role of CK2 inhibitor CX-4945 in anti-cancer combination therapy - potential clinical relevance
Claudio D'Amore et al.
CELLULAR ONCOLOGY (2020)
Pharmacological effects of harmine and its derivatives: a review
Liang Zhang et al.
ARCHIVES OF PHARMACAL RESEARCH (2020)
How to Separate Kinase Inhibition from Undesired Monoamine Oxidase A Inhibition-The Development of the DYRK1A Inhibitor AnnH75 from the Alkaloid Harmine
Anne Wurzlbauer et al.
MOLECULES (2020)
Expression, purification and crystallization of CLK1 kinase - A potential target for antiviral therapy
Noa Dekel et al.
PROTEIN EXPRESSION AND PURIFICATION (2020)
The novel DYRK1A inhibitor KVN93 regulates cognitive function, amyloid-beta pathology, and neuroinflammation
Hyun-ju Lee et al.
FREE RADICAL BIOLOGY AND MEDICINE (2020)
An isothermal shift assay for proteome scale drug-target identification
Kerri A. Ball et al.
COMMUNICATIONS BIOLOGY (2020)
DYRK1A and cognition: A lifelong relationship
Maria L. Arbones et al.
PHARMACOLOGY & THERAPEUTICS (2019)
Inhibition of DYRK1A proteolysis modifies its kinase specificity and rescues Alzheimer phenotype in APP/PS1 mice
Benoit Souchet et al.
ACTA NEUROPATHOLOGICA COMMUNICATIONS (2019)
Tau pathology reduction with SM07883, a novel, potent, and selective oral DYRK1A inhibitor: A potential therapeutic for Alzheimer's disease
Benoit Melchior et al.
AGING CELL (2019)
The crystal structure of the protein kinase HIPK2 reveals a unique architecture of its CMGC-insert region
Christopher Agnew et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2019)
SM04690, A POTENTIAL DISEASE-MODIFYING TREATMENT FOR KNEE OSTEOARTHRITIS, FUNCTIONS THROUGH INHIBITION OF CLK2 AND DYRK1A, NOVEL MOLECULAR REGULATORS OF WNT SIGNALING, CHONDROGENESIS, AND INFLAMMATION
V. Deshmukh et al.
OSTEOARTHRITIS AND CARTILAGE (2019)
Modulation of the Wnt pathway through inhibition of CLK2 and DYRK1A by lorecivivint as a novel, potentially disease-modifying approach for knee osteoarthritis treatment
V. Deshmukh et al.
OSTEOARTHRITIS AND CARTILAGE (2019)
Validation of the protein kinase PfCLK3 as a multistage cross-species malarial drug target
Mahmood M. Alam et al.
SCIENCE (2019)
Structural Basis for the Selective Inhibition of Cdc2-Like Kinases by CX-4945
Joo Youn Lee et al.
BIOMED RESEARCH INTERNATIONAL (2019)
Desmethylbellidifolin From Gentianella acuta Ameliorate TNBS-Induced Ulcerative Colitis Through Antispasmodic Effect and Anti-Inflammation
Yajuan Ni et al.
FRONTIERS IN PHARMACOLOGY (2019)
Inhibition of dual-specificity tyrosine phosphorylation-regulated kinase 2 perturbs 26S proteasome-addicted neoplastic progression
Sourav Banerjee et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2019)
Furo[3,2-b]pyridine: A Privileged Scaffold for Highly Selective Kinase Inhibitors and Effective Modulators of the Hedgehog Pathway
Vaclav Nemec et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2019)
X-ray Structures and Feasibility Assessment of CLK2 Inhibitors for Phelan-McDermid Syndrome
Joerg Kallen et al.
CHEMMEDCHEM (2018)
Dual-Specificity Tyrosine Phosphorylation-Regulated Kinase 1A (DYRK1A) Inhibitors as Potential Therapeutics
Dnyandev B. Jarhad et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
Ancient drug curcumin impedes 26S proteasome activity by direct inhibition of dual-specificity tyrosine-regulated kinase 2
Sourav Banerjee et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2018)
DYRK1A inhibition and cognitive rescue in a Down syndrome mouse model are induced by new fluoro-DANDY derivatives
Fernanda Neumann et al.
SCIENTIFIC REPORTS (2018)
Correction of cognitive deficits in mouse models of Down syndrome by a pharmacological inhibitor of DYRK1A
Thu Lan Nguyen et al.
DISEASE MODELS & MECHANISMS (2018)
DYRK1A kinase inhibition with emphasis on neurodegeneration: A comprehensive evolution story-cum-perspective
Ankita Pathak et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2018)
Novel selective thiadiazine DYRK1A inhibitor lead scaffold with human pancreatic β-cell proliferation activity
Kunal Kumar et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2018)
New and emerging therapies for acute myeloid leukaemia
Julian R. Davis et al.
JOURNAL OF INVESTIGATIVE MEDICINE (2018)
Novel Scaffolds for Dual Specificity Tyrosine-Phosphorylation-Regulated Kinase (DYRK1A) Inhibitors
Anna Czarna et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
A High-Throughput Screen Identifies DYRK1A Inhibitor ID-8 that Stimulates Human Kidney Tubular Epithelial Cell Proliferation
Maria B. Monteiro et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2018)
CC-401 Promotes β-Cell Replication via Pleiotropic Consequences of DYRK1A/B Inhibition
Yassan Abdolazimi et al.
ENDOCRINOLOGY (2018)
Midostaurin: its odyssey from discovery to approval for treating acute myeloid leukemia and advanced systemic mastocytosis
Richard M. Stone et al.
BLOOD ADVANCES (2018)
Seven Year Itch: Pan-Assay Interference Compounds (PAINS) in 2017-Utility and Limitations
Jonathan B. Baell et al.
ACS CHEMICAL BIOLOGY (2018)
Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature
Thu Lan Nguyen et al.
EXPERT OPINION ON THERAPEUTIC PATENTS (2017)
The Essential Medicinal Chemistry of Curcumin
Kathryn M. Nelson et al.
JOURNAL OF MEDICINAL CHEMISTRY (2017)
Marine-Derived 2-Aminoimidazolone Alkaloids. Leucettamine B-Related Polyandrocarpamines Inhibit Mammalian and Protozoan DYRK & CLK Kinases
Nadege Loaec et al.
MARINE DRUGS (2017)
Prenatal neurogenesis induction therapy normalizes brain structure and function in Down syndrome mice
Akiko Nakano-Kobayashi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2017)
CLK-dependent exon recognition and conjoined gene formation revealed with a novel small molecule inhibitor
Tyler Funnell et al.
NATURE COMMUNICATIONS (2017)
Inhibition of DYRK1A disrupts neural lineage specificationin human pluripotent stem cells
Stephanie F. Bellmaine et al.
ELIFE (2017)
Dyrk1A overexpression leads to increase of 3R-tau expression and cognitive deficits in Ts65Dn Down syndrome mice
Xiaomin Yin et al.
SCIENTIFIC REPORTS (2017)
Structure-Based Design and Synthesis of Harmine Derivatives with Different Selectivity Profiles in Kinase versus Monoamine Oxidase Inhibition
Balazs Balint et al.
CHEMMEDCHEM (2017)
An Unusual Binding Model of the Methyl 9-Anilinothiazolo[5,4-f]quinazoline-2-carbimidates (EHT 1610 and EHT 5372) Confers High Selectivity for Dual-Specificity Tyrosine Phosphorylation-Regulated Kinases
Apirat Chaikuad et al.
JOURNAL OF MEDICINAL CHEMISTRY (2016)
Discovery of (R,E)-N-(7-Chloro-1-(1-[4-(dimethylamino)but-2-enoyl]azepan-3-yl)-1H-benzo[d]imidazol-2-yl)-2-methylisonicotinamide (EGF816), a Novel, Potent, and WT Sparing Covalent Inhibitor of Oncogenic (L858R, ex19del) and Resistant (T790M) EGFR Mutants for the Treatment of EGFR Mutant Non-Small-Cell Lung Cancers
Gerald Lelais et al.
JOURNAL OF MEDICINAL CHEMISTRY (2016)
Probing the ATP-Binding Pocket of Protein Kinase DYRK1A with Benzothiazole Fragment Molecules
Ulli Rothweiler et al.
JOURNAL OF MEDICINAL CHEMISTRY (2016)
Tetrahydroxanthones from Mongolian medicinal plant Gentianella amarella ssp acuta
Shuangxin Lu et al.
JOURNAL OF NATURAL MEDICINES (2016)
Safety and efficacy of cognitive training plus epigallocatechin-3-gallate in young adults with Down's syndrome (TESDAD): a double-blind, randomised, placebo-controlled, phase 2 trial
Rafael de la Torre et al.
LANCET NEUROLOGY (2016)
Selective inhibition of the kinase DYRK1A by targeting its folding process
Isao Kii et al.
NATURE COMMUNICATIONS (2016)
Harmine stimulates proliferation of human neural progenitors
Vanja Dakic et al.
PEERJ (2016)
Design and synthesis of a potent inhibitor of class 1 DYRK kinases as a suppressor of adipogenesis
So Masaki et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2015)
Luciferin and derivatives as a DYRK selective scaffold for the design of protein kinase inhibitors
Ulli Rothweiler et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2015)
Leucettine L41, a DYRK1A-preferential DYRKs/CLKs inhibitor, prevents memory impairments and neurotoxicity induced by oligomeric Aβ25-35 peptide administration in mice
Gaelle Naert et al.
EUROPEAN NEUROPSYCHOPHARMACOLOGY (2015)
10-lodo-11H-indolo[3,2-c]quinoline-6-carboxylic Acids Are Selective Inhibitors of DYRK1A
Hannes Falke et al.
JOURNAL OF MEDICINAL CHEMISTRY (2015)
The n -> pi* interaction: a rapidly emerging non-covalent interaction
Santosh K. Singh et al.
PHYSICAL CHEMISTRY CHEMICAL PHYSICS (2015)
Inhibition of DYRK1A and GSK3B induces human β-cell proliferation
Weijun Shen et al.
NATURE COMMUNICATIONS (2015)
Unprecedented One-Pot Chemocontrolled Entry to Thioxoimidazolidinones and Aminoimidazolones: Synthesis of Kinase Inhibitor Leucettamine B
Manikandan Selvaraju et al.
ACS COMBINATORIAL SCIENCE (2015)
The structure of a dual-specificity tyrosine phosphorylation-regulated kinase 1A-PKC412 complex reveals disulfide-bridge formation with the anomalous catalytic loop HRD(HCD) cysteine
Marina Alexeeva et al.
ACTA CRYSTALLOGRAPHICA SECTION D-STRUCTURAL BIOLOGY (2015)
The casein kinase 2 inhibitor, CX-4945, as an anti-cancer drug in treatment of human hematological malignancies
Hee J. Chon et al.
FRONTIERS IN PHARMACOLOGY (2015)
Selectivity Profiling and Biological Activity of Novel β-Carbolines as Potent and Selective DYRK1 Kinase Inhibitors
Katharina Rueben et al.
PLOS ONE (2015)
A novel DYRK1B inhibitor AZ191 demonstrates that DYRK1B acts independently of GSK3β to phosphorylate cyclin D1 at Thr286, not Thr288
Anne L. Ashford et al.
BIOCHEMICAL JOURNAL (2014)
Epigallocatechin-3-gallate, a DYRK1A inhibitor, rescues cognitive deficits in Down syndrome mouse models and in humans
Rafael De la Torre et al.
MOLECULAR NUTRITION & FOOD RESEARCH (2014)
Design and Synthesis of Thiazolo[5,4-f]quinazolines as DYRK1A Inhibitors, Part II
Alicia Foucourt et al.
MOLECULES (2014)
Design and Synthesis of Thiazolo[5,4-f]quinazolines as DYRK1A Inhibitors, Part I
Alicia Foucourt et al.
MOLECULES (2014)
Identification of a Novel Function of CX-4945 as a Splicing Regulator
Hyeongki Kim et al.
PLOS ONE (2014)
Linking off-target kinase pharmacology to the differential cellular effects observed among PARP inhibitors
Albert A. Antolin et al.
ONCOTARGET (2014)
cdc-Like/Dual-Specificity Tyrosine Phosphorylation-Regulated Kinases Inhibitor Leucettine L41 Induces mTOR-Dependent Autophagy: Implication for Alzheimer's Disease
Xavier Fant et al.
MOLECULAR PHARMACOLOGY (2014)
Dual Specificity Kinase DYRK3 Couples Stress Granule Condensation/Dissolution to mTORC1 Signaling
Frank Wippich et al.
CELL (2013)
Development of DANDYs, New 3,5-Diaryl-7-azaindoles Demonstrating Potent DYRK1A Kinase Inhibitory Activity
Stephanie Gourdain et al.
JOURNAL OF MEDICINAL CHEMISTRY (2013)
Natural Aristolactams and Aporphine Alkaloids as Inhibitors of CDK1/Cyclin B and DYRK1A
Guillaume Marti et al.
MOLECULES (2013)
Computer-aided identification of novel protein targets of bisphenol A
Diana Montes-Grajales et al.
TOXICOLOGY LETTERS (2013)
7,8-Dichloro-1-oxo-β-carbolines as a Versatile Scaffold for the Development of Potent and Selective Kinase Inhibitors with Unusual Binding Modes
Kilian Huber et al.
JOURNAL OF MEDICINAL CHEMISTRY (2012)
Selectivity, Cocrystal Structures, and Neuroprotective Properties of Leucettines, a Family of Protein Kinase Inhibitors Derived from the Marine Sponge Alkaloid Leucettamine B
Tania Tahtouh et al.
JOURNAL OF MEDICINAL CHEMISTRY (2012)
Library-based Discovery of DYRK1A/CLK1 Inhibitors from Natural Product Extracts
Patrick Grabher et al.
PLANTA MEDICA (2012)
Developments in harmine pharmacology - Implications for ayahuasca use and drug-dependence treatment
Daniel I. Brierley et al.
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY (2012)
Wnt Signaling Orchestration with a Small Molecule DYRK Inhibitor Provides Long-Term Xeno-Free Human Pluripotent Cell Expansion
Kouichi Hasegawa et al.
STEM CELLS TRANSLATIONAL MEDICINE (2012)
Harmine is an ATP-competitive inhibitor for dual-specificity tyrosine phosphorylation-regulated kinase 1A (Dyrk1A)
Tatyana Adayev et al.
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS (2011)
Unprecedented Selectivity and Structural Determinants of a New Class of Protein Kinase CK2 Inhibitors in Clinical Trials for the Treatment of Cancer
Roberto Battistutta et al.
BIOCHEMISTRY (2011)
Synthesis and evaluation of beta-carboline derivatives as potential monoamine oxidase inhibitors
J. Reniers et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2011)
Specific CLK Inhibitors from a Novel Chemotype for Regulation of Alternative Splicing
Oleg Fedorov et al.
CHEMISTRY & BIOLOGY (2011)
Structural basis of CX-4945 binding to human protein kinase CK2
Andrew D. Ferguson et al.
FEBS LETTERS (2011)
Leucettines, a Class of Potent Inhibitors of cdc2-Like Kinases and Dual Specificity, Tyrosine Phosphorylation Regulated Kinases Derived from the Marine Sponge Leucettamine B: Modulation of Alternative Pre-RNA Splicing
Mansour Debdab et al.
JOURNAL OF MEDICINAL CHEMISTRY (2011)
β-Carboline Compounds, Including Harmine, Inhibit DYRK1A and Tau Phosphorylation at Multiple Alzheimer's Disease-Related Sites
Danielle Frost et al.
PLOS ONE (2011)
CX-4945, an Orally Bioavailable Selective Inhibitor of Protein Kinase CK2, Inhibits Prosurvival and Angiogenic Signaling and Exhibits Antitumor Efficacy
Adam Siddiqui-Jain et al.
CANCER RESEARCH (2010)
Synthesis and preliminary biological evaluation of new derivatives of the marine alkaloid leucettamine B as kinase inhibitors
Mansour Debdab et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2010)
Rapid-Response Splicing Reporter Screens Identify Differential Regulators of Constitutive and Alternative Splicing
Ihab Younis et al.
MOLECULAR AND CELLULAR BIOLOGY (2010)
Development of a novel selective inhibitor of the Down syndrome-related kinase Dyrk1A
Yasushi Ogawa et al.
NATURE COMMUNICATIONS (2010)
Harmine specifically inhibits protein kinase DYRK1A and interferes with neurite formation
Nora Goeckler et al.
FEBS JOURNAL (2009)
Discovery of 2-{4-[(3S)-Piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide (MK-4827): A Novel Oral Poly(ADP-ribose)polymerase (PARP) Inhibitor Efficacious in BRCA-1 and-2 Mutant Tumors
Philip Jones et al.
JOURNAL OF MEDICINAL CHEMISTRY (2009)
Dihydrostilbene Derivatives from the Mongolian Medicinal Plant Scorzonera radiata
Yao Wang et al.
JOURNAL OF NATURAL PRODUCTS (2009)
Green Tea Polyphenols Rescue of Brain Defects Induced by Overexpression of DYRK1A
Faycal Guedj et al.
PLOS ONE (2009)
DYRK3 Dual-specificity Kinase Attenuates Erythropoiesis during Anemia
Olga Bogacheva et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
Structure of human monoamine oxidase A at 2.2-Å resolution:: The control of opening the entry for substrates/inhibitors
Se-Young Son et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
c-Jun N-Terminal Kinase Signaling Inhibitors Under Development
Sun-Young Han
TOXICOLOGICAL RESEARCH (2008)
The selectivity of protein kinase inhibitors: a further update
Jenny Bain et al.
BIOCHEMICAL JOURNAL (2007)
DYRK1A-mediated hyperphosphorylation of Tau - A functional link between Down syndrome and Alzheimer disease
Soo-Ryoon Ryoo et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
GSK626616: A DYRK3 inhibitor as a potential new therapy for the treatment of anemia
Connie L. Erickson-Miller et al.
BLOOD (2007)
Synthesis and biological evaluation of sulfonylhydrazone-substituted imidazo[1,2-a]pyridines as novel PI3 kinase p110α inhibitors
Masahiko Hayakawa et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2007)
Epigallocatechin-3-gallate (EGCG): Chemical and biomedical perspectives
Dale G. Nagle et al.
PHYTOCHEMISTRY (2006)
A pharmacological map of the PI3-K family defines a role for p110α in insulin signaling
Zachary A. Knight et al.
CELL (2006)
A comparison of assay performance measures in screening assays:: Signal window, Z′ factor, and assay variability ratio
PW Iversen et al.
JOURNAL OF BIOMOLECULAR SCREENING (2006)
A pharmacological map of the PI3-K family defines a role for p110 alpha in insulin signaling
Zachary A. Knight et al.
CELL (2006)
Cell differentiation, caspase inhibition, and macromolecular synthesis blockage, but not BCL-2 or BCL-XL proteins, protect SH-SY5Y cells from apoptosis triggered by two CDK inhibitory drugs
J Ribas et al.
EXPERIMENTAL CELL RESEARCH (2004)
Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412
E Weisberg et al.
CANCER CELL (2002)
Microwave-mediated solventless synthesis of new derivatives of marine alkaloid Leucettamine B
JR Chérouvrier et al.
TETRAHEDRON LETTERS (2002)
The kinase DYRK phosphorylates protein-synthesis initiation factor eIF2Bε at Ser539 and the microtubule-associated protein tau at Thr212:: potential role for DYRK as a glycogen synthase kinase 3-priming kinase
YL Woods et al.
BIOCHEMICAL JOURNAL (2001)
A new bioactive triene aldehyde from the marine sponge Leucetta microraphis
K Watanabe et al.
JOURNAL OF NATURAL PRODUCTS (2000)
Share Paper
